Previous 10 |
Gainers: MICT (NASDAQ: MICT ) +52% . More news on: MICT, Inc., RISE Education Cayman Ltd, Forward Industries, Inc., Stocks on the move, , Read more ...
Recent IPO Poseida Therapeutics ( PSTX -29.8% ) hits its first major pothole with a potential safety signal in a Phase 1 clinical trial evaluating autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer. More news on: Poseida Therapeutics,...
Seanergy Maritime Holdings (NASDAQ: SHIP ) -52% after pricing public offering of ~35.7M units. More news on: Seanergy Maritime Holdings Corp., Poseida Therapeutics, Inc., Comstock Mining Inc., Stocks on the move, , Read more ...
Poseida Therapeutics (NASDAQ: PSTX ) -34.5% after-hours on disclosing that the Food and Drug Administration halted a safety trial of the company's P-PSMA-101 prostate cancer treatment because of the death of a patient enrolled in the study. More news on: Poseida Therapeutics, In...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Inc. Website:
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advanci...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...